RCT | Cilta-cel shows superior progression-free survival over standard care in lenalidomide-refractory multiple myeloma

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Findings suggest cilta-cel may be key therapeutic option for patients with multiple myeloma after first relapse – Medical College of Wisconsin

Commentary: CARTITUDE-4 Shows Benefit With Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma – ASCO Daily News

Commentary on Twitter

Original Article: Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4) https://t.co/Wag2UTKOfH#ASCO23

— NEJM (@NEJM) June 6, 2023